Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China

doi:10.4251/wjgo.v18.i4.113266

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 4

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (91)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-5)

Tables (1-4)

Sum=45

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=53

Apr 15, 2026 (publication date) through Apr 11, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Apr 15, 2026; 18(4): 113266
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.113266

Open in New Tab Full Size Figure Download Figure

Figure 1 Flowchart of the literature search and selection process. The REFLECT and LEAP-002 trials reported Chinese subgroup data at Chinese Society of Clinical Oncology 2017 and Asian Pacific Association for the Study of the Liver 2024, respectively. HCC: Hepatocellular carcinoma; RCT: Randomized controlled trial; WoS: Web of Science.

Open in New Tab Full Size Figure Download Figure

Figure 2 Partitioned survival model. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization.

Open in New Tab Full Size Figure Download Figure

Figure 3 Tornado diagrams of one-way sensitivity analyses, using sorafenib as the comparator, the top ten variables were showed. BSC: Best supportive care; HR: Hazard ratio; L + T: Lenvatinib plus transarterial chemoembolization; OS: Overall survival; PD: Progressive disease; PFS: Progression-free survival; R + C: Rivoceranib plus camrelizumab; Sora: Sorafenib; TACE: Transarterial chemoembolization; Tori: Toripalimab.

Open in New Tab Full Size Figure Download Figure

Figure 4 Probabilistic sensitivity analysis scatter plot for each treatment compared with sorafenib. QALY: Quality-adjusted life year; TACE: Transarterial chemoembolization.

Open in New Tab Full Size Figure Download Figure

Figure 5 Cost-effectiveness acceptability curves under different willingness-to-pay thresholds. TACE: Transarterial chemoembolization.

Citation: Lin ZH, He Y, Xu HX, Xiao L. Cost-effectiveness analysis of seven treatments vs sorafenib as first-line therapy for advanced hepatocellular carcinoma in China. World J Gastrointest Oncol 2026; 18(4): 113266
URL: https://www.wjgnet.com/1948-5204/full/v18/i4/113266.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i4.113266